Cat. No. 1571
Alternative Names: Elatericin B, JSI 124
Chemical Name: (9β,10α,16α,23E)-2,16,20,25-Tetrahydro
Biological ActivitySelective inhibitor of STAT3/JAK2 signaling. Inhibits the activation of STAT3 and JAK2 and displays no activity on Src, Akt, ERK and JNK. Suppresses phosphotyrosine levels of STAT3, inhibits STAT3 DNA binding and STAT3-mediated gene expression. Induces apoptosis in cell lines expressing constitutively active tyrosine-phosphorylated STAT3.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Blaskovich et al (2003) Discovery of JSI-124 (cucurbitacin I), a selective janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res. 63 1270. PMID: 12649187.
Nefedova et al (2005) Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res. 65 9525. PMID: 16230418.
Dziennis et al (2007) Role of signal transducer and activator of transcription-3 in estradiol-mediated neuroprotection. J.Neurosci. 27 7268. PMID: 17611279.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Cucurbitacin I, supplier, Selective, inhibitors, STAT3/JAK2, signaling, signalling, Janus, Activated, Kinase, JAK, Kinases, Signal, Transducers, activators, Transcription, STAT, CucurbitacinI, ElatericinB, JSI124, Tocris Bioscience, JAK Inhibitors
Find multiple products by catalog number
New Products in this Area
PKC activator; also NF-κB activatorTBCA
Selective CK2 inhibitorMSC 2032964A
Potent and selective ASK1 inhibitor; orally bioavailableCW 008
PKA signaling activator; promotes osteogenesis from hMSCsPF 06447475
Potent LRRK2 inhibitor; neuroprotectiveAMG PERK 44
Potent and selective PERK inhibitor; orally bioavailableCGP 60474
Potent dual cdk1/cdk2 inhibitorCGP 74514 dihydrochloride
Potent cdk1 inhibitorKG 5
PDGFRβ, B-Raf, c-Raf, FLT3 and KIT inhibitorNilvadipine
Syk kinase inhibitor; inhibits Aβ productionCentrinone B
High affinity and selective PLK4 inhibitorHTH 01-015
Potent and selective NUAK1 inhibitorKobe 0065
H-Ras-cRaf1 interaction inhibitor; inhibits Raf signalingOSU 03012
PDK1 inhibitor; inhibits Akt signalingSR 7826
Potent and selective LIMK inhibitor; antitumorMps BAY 2a
Potent and selective Mps1 kinase inhibitorNG 25
TGF-β-activated kinase (TAK1) inhibitorMI 14
Potent and selective PI 4-kinase IIIβ inhibitorCTA 056
ITK inhibitorAZD 1480
Potent and selective JAK2 inhibitor; antiangiogenicTC-S 7001
Potent and highly selective ROCK inhibitor; orally activeAS 2444697
Potent and selective IRAK4 inhibitor
March 19 - 23, 2016
Denver, CO, USA